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There is a growing recognition that nutrition may have a positive impact on public health
and that it may reduce medical expenditures. Yet, such claims need to be substantiated
by evidence. This evidence could be delivered by health technology assessment (HTA),
which can be thought of as the evaluation of technologies for clinical effectiveness, cost-
effectiveness, and ethical, legal, and social impacts. The application of HTA to the field of
“nutrition interventions” is recent. So far, HTA and nutrition have represented two worlds
far apart in many respects. This contribution, roughly, addresses the following issues: is
there a need for HTAs in the field of nutrition, what would such HTAs look like, and how
can the results coming from these HTAs optimally aid policy making?
In essence, HTAs of nutrition have much of the same basic principles and structure as
HTAs of “classical” health care treatments. Nevertheless, there are challenges to rigorous
HTAs of nutrition interventions, for various reasons. To mention a few: the evidence base
for nutrition interventions is less well developed than that for many health care treatments.
Furthermore, it is a matter of debate which outcome measures should be used in HTAs of
nutrition. For example, one may argue that nutrition not only has health effects, but also
effects that are not captured by traditional health-related quality of life measures (e.g., the
pleasure of eating, effects relating to ease of use, or effects on well-being).
HTAs in the field of nutrition may deliver information valuable to a wide
range of stakeholders, including consumers/patients, health professionals, hospital
administrators, insurers, and decision makers. The results of HTAs are typically used in
making treatment guidelines, in informing decisions about reimbursement or about public
health campaigns, etc. Yet, it is uncertain how the results of HTAs of nutrition can be used
optimally. For example, would it be possible to summarize the results of a HTA in a single
ratio (such as costs per quality-adjusted life-year gained) and then to either approve or
reject the intervention based on this ratio, compared to a certain threshold? Apart from
that, in the field of nutrition, it is typically not about reimbursement of a technology. Related
to this, it is important that the message from HTAs of nutrition is brought to a range of
stakeholders including the general population and that these HTAs are tailored to the
decision-making context.
To conclude, a growing need is felt for HTA-type evaluations of nutrition, which are
sparse these days. Little thought has been given to developing an optimal methodology
for HTAs of nutrition and to how its results should be integrated into policy making. Further
work in these areas would stimulate the development of nutrition interventions that yield
a gain in societal welfare. To achieve this, the two worlds of HTA and nutrition need to be
brought together.
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INTRODUCTION
Over the last decades, the pattern of disease shifted from
acute diseases to chronic diseases, which are of long duration
and generally slow progression. The main types of chronic
diseases, also known as non-communicable diseases (NCDs), are
cardiovascular diseases, cancers, chronic respiratory diseases, and
diabetes. NCDs account for 38 million deaths each year (World
Health Organization, 2014). One of the risk factors of NCDs is
an unhealthy diet, next to other behavioral risk factors (such as
tobacco use) and metabolic/physiological risk factors.
Due to developments like these, there is a growing recognition
of the positive impact that nutrition may have on health. This
holds for many diseases. To give one example, it has been
calculated that 25% of all cancers could be prevented by the
right nutrition, together with sufficient physical activity and a
healthy body weight (World Cancer Research Fund andAmerican
Institute for Cancer Research, 2007). Accordingly, it has been
recognized that diet changes have the potential to reduce medical
expenditures by considerable amounts. For example, it has been
calculated in the United States that a permanent reduction of
100 kilocalories in daily intake would result in savings of related
medical costs of 58 billion dollars annually, as it would eliminate
some 70 million cases of obesity or overweight (Dall et al., 2009).
In this context, it should be noted that nutrition cannot only be
effective in the long-term prevention of diseases. It may also have
a role in the management of specific disease areas. For example,
food supplements or dietary modifications may lead to cognitive
improvement (or at least a delayed decline) in patients with early
Alzheimer’s disease (Shah, 2013; Swaminathan and Jicha, 2014).
To give another example, probiotics have been demonstrated to
be beneficial in preventing acute upper respiratory tract infections
and in reducing the duration of illness episodes (King et al.,
2014; Hao et al., 2015). Finally, nutrition interventions may
also have positive effects in the short term: for example, oral
nutritional supplements in malnourished hospitalized patients
have repeatedly been shown to be associated with a reduced
length of hospital stay and thus cost savings (Freijer et al., 2014;
Lakdawalla et al., 2014; Walzer et al., 2014).
So, on the whole, it seems that nutrition can havemany positive
societal effects, in terms of public health and health care costs.
Yet, however encouraging this observation is, such claims need
to be substantiated by evidence on its positive outcomes, in
relation to the additional cost (or: savings) that it may bring
about. A discipline that seems well suited to deliver this kind of
evidence is called health technology assessment (HTA). HTA has
developed strongly over the last decades. From the beginning its
intent was to consider the social impact of medical technologies,
in order to enable optimal decisions regarding the use and
reimbursement of such technologies. HTA has been described as
the evaluation of high-priority technologies for efficacy, safety,
cost-effectiveness, and current and potential economic, ethical,
legal, and social impacts (Perry and Eliastam, 1981). So, HTA
takes a multidisciplinary approach, yet assessing the economic
impact of health technologies—that is, the balance between
costs and (health) benefits—has prevailed in practice. In this
respect, the term nutrition economics (as a novel branch of
health economics) has become increasingly popular in the field
of nutrition (Lenoir-Wijnkoop et al., 2011, 2012; Koponen et al.,
2012). In the context of this paper, the term HTA will be used,
as it intends to take a broad look at the assessment of nutrition
interventions, extending beyond economic impacts alone. But also
here, the focus will be on the economic evaluation of nutritional
interventions.
Information derived from HTAs has played a growing role in
health care decision-making. HTA offers a source of information
needed by, for example, policymakers in formulating regulations,
by industry in developing products, by health professionals in
treating and serving patients, and by consumers in making
personal health decisions. It is in line with current trends of
evidence-based medicine, where the evidence is not limited to
evidence on “clinical” effectiveness only, and growing (financial
and other) constraints on the health care sector. To be funded
from public funds, interventions increasingly need to have
demonstrated safety, effectiveness, and value for money.
The application of HTA to the field of nutrition is recent.
That is, from its origin, HTA has mainly been applied to
“classical” health care treatments, especially to pharmaceutical
interventions and high-technology, expensive treatments such as
organ transplantation, kidney dialysis, et cetera. Recently, the
conviction has been growing that HTA should also be applied to
“nutrition interventions.” Early examples of HTAs in the field of
nutrition include HTAs of home parenteral nutrition and HTAs
of nutrition interventions targeting disease-related malnutrition.
However, nutrition does not parallel health care treatments.
Consider that, as will be further explained below, there are many
differences for example regarding the “technology” itself, the
target population, the policy context, and so on. Consequently,
HTAs of nutrition are not necessarily identical to HTAs of health
care treatments.
To shed light on some of the questions surrounding the
application of HTA to the field of nutrition, this contribution will
address the following main questions:
- Is there a need for HTAs in the field of nutrition? Can nutrition
interventions be regarded as “health technologies”?
- What would aHTA in the field of nutrition look like, compared
to HTAs of “classical” health care interventions?
- Does a HTA in the field of nutrition require other outcome
measures, compared to HTAs of “classical” health care
interventions?Would the concept of quality of life be a suitable
outcome measure?
- How can the results coming from these HTAs optimally aid
policy making?
THE NEED FOR HTAS IN THE FIELD
OF NUTRITION
Like mentioned above, HTAs have typically focused on “classical”
health care treatments, especially on pharmaceuticals and high-
technology, expensive treatments. That is, technologies that are
used in patients with a diagnosis, that are prescribed by a
doctor, and frequently have a direct, observable effect. Nutrition
interventions clearly need to be distinguished from health care
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treatments, for several reasons. They have a different working
mechanism: as noted by de Vos et al. (2006), whereas drugs
generally contain a single effective component that is specific and
only has one target site in the body (producing a large effect),
foods consist of a variety of components and can have effects on
multiple targets (usually small effects). Furthermore, foods often
sort an effect on the long-term, and finally, they are used (mostly
on the individual’s own initiative) not only for health purposes,
but for other reasons as well (i.e., as a means to stay alive, to satisfy
hunger, for pleasure). In addition, foods are consumed every
day throughout life, whereas health care treatments are usually
required for a short period of time. Finally, to be successful,
nutrition interventions often require a change of habits. All this
is further complicated by the fact that nutrition covers a wide
range of food categories: from conventional food, to functional
food, to infant food, to (enteral and parenteral) medical nutrition.
So, at least they should be seen as diverse and atypical health
technologies.
Nevertheless, there is a need for HTAs in the field of nutrition.
Classical HTAs originated from the need that was felt to support
decisions regarding the introduction of a technology to the
market, reimbursement from the collective insurance, adoption
in treatment guidelines, etc. HTAs in nutrition may deliver
information that may be valuable to consumers/patients (who
have to decide on buying a food product, the costs of which they
have to bear themselves), to health professionals (who decide on
prescribing of medical nutrition for example), to insurers (who
may consider to reimburse functional foods for example) and
to decision makers (who are responsible for investing in public
educational campaigns and for regulating processes related to
food labeling and health claims). This shows thatHTA in nutrition
is a broad field, which is also shown by the diversity of the
subjects covered. These may range from studies of micronutrient
deficiencies andmalnutrition, to studies of dietary improvements,
to studies of functional foods (Gyles et al., 2012). To use another
categorization showing the variety of the area of interest: HTAs
in nutrition may study subjects as diverse as interventions at the
individual level (e.g., advice on diet), interventions at the group
level (e.g., group education in schools), and interventions at the
population level (e.g., taxes on unhealthy foods).
HTAS OF NUTRITION
Having said this, one may wonder what a HTA in nutrition
would look like, compared to HTAs of “classical” health care
interventions. Is there a need to use adapted techniques, or would
regular HTA methods, as they have been developed and refined
over the last decades, suffice?
As it will be argued below, in essence, HTAs of nutrition
have much of the same basic principles and structure as HTAs
of health care, just like the main purpose of those HTAs is the
same (i.e., to inform technology-related policy making in health
care, against the background of scarce resources). In each field
of interest, HTA will basically follow the same steps. Consider
for example the 10 basic steps of HTA set out by Goodman
and Ahn (1999): (1) Identify assessment topics; (2) Specify the
assessment problem; (3) Determine locus of assessment; (4)
Retrieve evidence; (5) Collect new primary data (as appropriate);
(6) Interpret evidence; (7) Synthesize/consolidate evidence; (8)
Formulate findings and recommendations; (9) Disseminate
findings and recommendations; (10) Monitor impact.
Nevertheless, there are challenges to rigorousHTAs of nutrition
interventions, for various reasons. To mention a few: assessment
of nutrition interventions has traditionally mainly relied on
non-experimental methods, such as cohort studies, case-control
studies, or surveys, as randomized controlled trials (RCTs) are
ill-suited for the evaluation of nutrition (Heaney, 2008). So, its
evidence base is less well developed than that for many health
care treatments, lacking high-quality evidence of cause and effect.
Furthermore, also given the absence of RCTs, confounding factors
may be present in HTAs of nutrition. This is because people
may change their behaviors in other ways as well (as part of an
overall lifestyle change), apart from just starting to consume a food
product. Next, there is less practical HTA experience in nutrition
than in other technologies, such as drugs. Finally, it is a matter of
debate which outcome measures can and should be used in HTAs
of nutrition, which is the focus of the next section.
So, to conclude, there are specific demands to HTAs of
nutrition, which may require such HTAs to move away from
traditional HTA methods. Importantly, however, this does not
only apply to nutrition, but to other areas as well: for example,
the evaluation of public health interventions and long-term
(palliative) care services may also raise additional methodological
challenges, as has been noted in the literature (Gomes et al.,
2009; Weatherly et al., 2009). HTAs of nutrition interventions can
benefit from developments in these other areas (and vice versa),
given that the methodological issues partly coincide with each
other.
OUTCOME MEASURES USED IN HTAS
OF NUTRITION
One of the questions is whether HTAs in the field of nutrition
require other outcome measures, compared to HTAs of “classical”
health care interventions? In the field of HTA, outcome measures
have been developed, to capture the effects of health technologies
on patients’ length of life (mortality) and on quality of life.
Especially, a large interest has been dedicated to health-related
quality of life (HRQoL). HRQoL has been defined as “the physical,
psychological, and social domains of health, seen as distinct areas
(or domains) that are influenced by a person’s experiences, beliefs,
expectations, and perceptions” (Testa and Simonson, 1996). So,
HRQoL is a multidimensional construct, encompassing physical,
emotional, and social domains. Furthermore, it is about the
subjective perception of the relevance and importance of health
states to the individual.
Would the concept of HRQoL be a suitable outcomemeasure in
nutrition? To answer this question, a number of observations are
worth noting. First, nutrition has effects that are indeed relevant
to the patient and that may be captured by measures of HRQoL.
Quality-adjusted life-years (QALY), a common outcome measure
in HTA, can be used. This has been done, for example, in studies
on medical nutrition (Freijer et al., 2014) and in studies on
public health interventions, aimed at decreasing fat or sodium
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intake (Smith-Spangler et al., 2010; Bos et al., 2011). This leaves
unaffected that, in the design of a HTA study, measures of
HRQoL may be combined with other outcome measures, such as
biological and physiological variables (i.e., changes in cell, organ
and organ system function) and traditional nutritional outcomes
such as energy intake, weight gain, and BMI. For example, one
may think of the impact of prebiotic and probiotic foods on
the improvement of gut flora, which has attracted much interest
recently. Furthermore, it must be realized that nutrition may have
an effect only over a long time span, which will have to be taken
into account when designing and performing HTAs. Yet, this is
not only true for nutrition, it does also apply to some (preventive)
health care technologies. So, in sum, if a nutrition intervention
aims to increase health, HRQoL measures such as the QALY may
be perfectly suitable. However, nutrition may have effects that are
not captured by traditional HRQoL measures. We may think of
taste, the pleasure of eating, effects relating to comfort or ease
of use, effects on well-being or happiness, or intermediate effects
on health such as a quicker recovery from surgery or quicker
recuperation time needed before receiving a next treatment. This
may give nutrition interventions a comparative advantage, ceteris
paribus, relative to health care treatments. For example, it may
be more pleasurable to eat margarine, yogurt, etc. than to take
a drug, just like people may prefer taking a drug to surgery. If
an intervention also aims to bring such other “broader” positive
effects (other than HRQoL), appropriate outcome measures must
be sought to capture the full benefits of nutrition.
Obviously, people attach importance to the health outcomes of
health care treatments (and health systems). Yet, there is evidence
now that people also care about the processes that precede health
outcomes, irrespective of whether they affect health. This has
been labeled “process utility” (i.e., utility derived from processes;
Donaldson and Shackley, 1997; Ratcliffe and Buxton, 1999;
Brennan and Dixon, 2013). Characteristics relating to the process
of care may include factors such as invasiveness of the treatment,
location and context of the treatment provided, continuity of staff,
being treated with dignity, and level of autonomy experienced by
the patient. To achieve optimal resource allocation, HTAs should
take into account utility resulting from the process of care, next to
health gains. This is especially relevant when the field of interest
is so broad as to encompass health care interventions (which may
range from curative care to preventative care, to comfort care and
palliative care) and nutrition interventions.
Finally, it should be recognized that nutrition can have
effects on others than the patient/consumer him or herself,
which should be taken into consideration in HTA studies (like
it is increasingly done in HTAs of health care treatments).
Currently, there is only limited evidence on this. One study, for
example, evaluated the impact of gastrostomy tube feeding on
the HRQoL of carers of children with cerebral palsy. The study
reported a significant improvement in the carers’ HRQoL after
insertion of a gastrostomy feeding tube, coupled with a significant
reduction in feeding times (Sullivan et al., 2004). A recent RCT
in newborns with functional gastrointestinal disorders showed
that daily administration of a probiotic decreased the onset of
gastrointestinal disorders, reduced daily crying time, and led
to overall cost savings, by reducing both health care use and
lost parental working days (Indrio et al., 2014). These examples
highlight that HTAs should take into account effects on others,
as nutrition interventions may alleviate the burden on caregivers,
improve theirHRQoL, avoid productivity losses, andbe associated
with cost savings.
PUTTING THE EVIDENCE OF HTAS
OF NUTRITION INTO PRACTICE
The result of anyHTA is an assessment of the value (for money) of
a health technology. This may, for example, involve the economic
costs and clinical effectiveness of a technology, but also ethical and
legal pros and cons, the social impact, etc. The results of HTAs
are typically used in making treatment guidelines, in informing
decisions about reimbursement (in- or exclusion from the benefits
package) or about public health campaigns, etc.
The results of a conventional HTA may be summarized in
a so-called incremental cost-effectiveness ratio (ICER), which
expresses the extra costs required to achieve one additional
unit of benefit, such as costs per life-year gained or costs per
QALY gained. When the results of an HTA are being used in
this way, some threshold would be practical beyond which the
technology will not be recommended (approved for funding).
However, in no single country, an absolute threshold is being
used by decision-makers. Yet, in practice, the chance of rejection
increases with decreasing cost-effectiveness. For example, in the
UK, it seems that technologies costing £40,000 per QALY have
a 50% chance of being rejected (75% at £52,000/QALY; 25% at
£27,000/QALY; Dakin et al., 2014). Apparently, it is difficult to
fix a certain threshold, and apply it uniformly. There has been
plenty of discussion about whether the outcomes should be valued
differently for different areas of health care, for example life-
threatening severe diseases, treatments targeted at children rather
than older people, comfort care rather than curative care, rare
diseases, diseases that can be attributed to the responsibility and
choice of the individual, etc. (van de Wetering et al., 2014). This
suggests that other arguments, most notably equity, play a role
in decisions about recommending for or against a technology.
Even within health care, we as a society seem to be willing to pay
more (i.e., accept a higher threshold) for certain technologies (and
disease areas) than for others. What about interventions in the
field of nutrition? This is far from clear yet, but likely is related
to the characteristics of the beneficiaries.
Furthermore, and perhaps more importantly, it may be
reminded here that in the field of nutrition, it is typically not
about reimbursement of a technology. Although there have
been examples, food products are typically not reimbursed
by a third-party payer, but instead paid for out-of-pocket by
consumers. Related to this, especially in the area of nutrition,
it is important that the message from HTA is brought to the
general population (rather than mainly to health care providers
or decision-makers). The public could be stimulated tomake good
food choices, as such, putting the results from HTA into practice.
This may be challenging, because consumer food choices are
affected bymany different factors, including nutrition knowledge,
sensory preferences, cost, availability and access to stores,
cultural background, social environment, and food marketing
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(Larson and Story, 2009). This is quite different from health care
settings, where, roughly speaking, patients follow their doctor-
prescribed regimen (even though the issue of non-compliance
must not be underestimated). HTAs in nutrition should ideally
take this into account. As a general note, it is worth mentioning
here that HTAs of nutrition should target the information needs
of different stakeholders, which may include both policy makers,
hospital administrators, and the general public. Any HTA of
nutrition should think about the following questions: who is the
decisionmaker that needs to informed, which information ismost
relevant to this decision maker, and what is the decision making
context?
CONCLUSION
This paper focused attention on HTA and nutrition, two
worlds far apart in many respects so far. Increasingly, the need
is felt for HTA-type evaluations of nutrition, which provide
information relevant to a wide range of stakeholders, including
consumers/patients, health professionals, hospital administrators,
insurers, and decision makers. Yet, currently, such evaluations,
delivering evidence on the social impact of nutrition, are sparse.
Moreover, little thought has been given to developing an optimal
methodology for HTAs of nutrition, that is, whether current HTA
methods suffice or would need adaptation to capture the specific
nature of nutrition. Then, a better understanding is required
of how to optimally orient HTAs of nutrition to the needs of
policy makers and how to integrate the results of these HTAs
into policy making (e.g., what criteria can be used to decide
for or against a certain nutrition intervention and where to
draw the line between cost-effective and cost-ineffective nutrition
interventions). Further work in all these areas would stimulate
the development of nutrition interventions that generate positive
effects on society’s health, and that do so at a reasonable additional
cost (or are even associated with cost savings). So, there is a
potential gain in societal welfare. To achieve this, the two worlds
of HTA and nutrition need to be brought together.
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